UCB SA Deal History & Licensing Activity
UCB SA is a large pharma headquartered in Belgium. Over the past three years, UCB SA has been involved in 2 licensing and acquisition transactions, with a primary focus on Cell Therapy (2 deals). The company currently has 50 active clinical trials, primarily in CNS Disorders.
Deals (12mo)
3
Active Trials
50
Top Modality
Cell Therapy
Focus Area
CNS Disorders
UCB SA Recent Deal Activity
Licensing, acquisition, and partnership transactions involving UCB SA in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| early-stage seizure cell therapy | UCB | Cell Therapy | Preclinical | acquisition | Apr 2026 |
UCB SA Pipeline Focus
Therapeutic areas and modalities where UCB SA is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
UCB SA Strategic Signals
Key indicators of UCB SA's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
UCB SA Clinical Pipeline
UCB SA has 50 active clinical trials across 6 development phases.
7
Unknown
2
Not Applicable
3
Phase 4
7
Phase 1
4
Phase 2
27
Phase 3
See How Your Asset Matches UCB SA's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for CNS Disorders assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cell Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for cell therapy deals
Mab Benchmarks
Upfront, milestone, and royalty benchmarks for mab deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About UCB SA Licensing & Deal Activity
UCB SA is a large pharma company based in Belgium that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, UCB SA ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for UCB SA include CNS Disorders (20 deals and trials), Autoimmune (16 deals and trials), Mega Deals (2 deals and trials), and Dermatology (1 deal and trial). In terms of modality, UCB SA has shown particular interest in cell therapy, mab.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for UCB SA and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against UCB SA's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.